Vulvodynia Treatment Market, Size, Share, Growth, Trends, Insight and Industry Forecast, 2021-2028

SKU: DMPH2196 | Last Updated On: Jan 21 2021 | No. of Pages: 180 | Available Formats

> Global Vulvodynia Treatment Market Expected to reach a high CAGR of 6.1% By 2027: DataM Intelligence

Global Vulvodynia Treatment Market is segmented By Drug type (Anticonvulsants, Tricyclic antidepressants, Local anesthetics, Antimicrobials, Hormone creams, Nerve blocks, others), By End-user (Hospital Pharmacies, Retail pharmacies, Online pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2020-2027

 

Market Overview

The Global Vulvodynia Treatment Market is expected to grow at a CAGR of 6.1% during the forecasting period (2020-2027).

Vulvodynia is chronic vulvar pain or discomfort with unexplained, multifactorial etiology that can occur in women of all ages and reproductive stages. The complex etiology of the diseases and the symptoms of comorbid pain conditions make the management difficult.

Source: DataM Intelligence Analysis (2019)

Market Dynamics

The major driving forces are the increasing concerns and the growing awareness programs that are related to women's healthcare, the advancements in the healthcare facilities and the diagnostic services, the availability of a large number of generic products.

The presence of an increasing number of research and development activities is expected to drive the market. For instance, according to an article published on February 16, 2017, with the new funding from the Mayday Fund of $363,000, SLU scientists examined the potential biomarkers for pain linked to debilitating health conditions like chemotherapy-induced peripheral neuropathy (CIPN), endometriosis, interstitial cystitis, and vulvodynia. Also, according to an article published on October 11, 2017, Schlaeger, assistant professor at the University of Illinois at Chicago's College of Nursing, has received a $2 million, five-year grant from the National Institute of Health's National Institute of Child Health and Human Development to study whether acupuncture can treat vulvodynia, a women's chronic pain condition.

The rising incidence of vulvodynia is expected to drive market growth over the forecast period. For instance, according to a study conducted by the University of Michigan, 1 in 4 women will experience vulvar pain at some point in their lifetime. Like all other medical concerns, vulvar pain causes both physical and mental stress.

The presence of a promising product pipeline is expected to drive market growth over the forecast period. For instance,

Company

Drug

Indication

Phase

Anticipated launch

Ipsen Pharma

Biological-Botulinum toxin type A

Vulvodynia

Phase 2

December 2020

GTO Pharmaceutical, LLC

Sinecatechins Topical

Vulvodynia, Dyspareunia, and others

Phase 2

September 2020

However, low awareness, the onset of side effects from the treatment medications, and the absence of the diagnosis of the disease are expected to restrain the market growth.

The onset of side effects associated with the treatment like hives, difficulty breathing, swelling of the face, lips, tongue, or throat, blurred vision, etc. are likely to hamper the market growth.

Market Segmentation

Based on the drug type, the global vulvodynia treatment market is segmented into local anaesthetics, anticonvulsants, tricyclic antidepressants, antimicrobials, hormone creams, nerve blocks, and others.

The anti-convulsant segment is expected to grow at a high rate over the forecast period. In vulvodynia treatment, anticonvulsant is the most prescribed drug. Gabapentin is the most reliable anticonvulsant drug available in vulvodynia treatment. Gabapentin is a drug which was recognized in chronic pain management as an effective way of curing pain. Pregabalin is another anticonvulsant drug. It is similar to Gabapentin. However, it is demonstrated to have less side effects and is possibly more operative. The presence of an increased number of research and development activities is expected to boost the growth of the market. For instance, according to an article published in the American Journal of Obstetrics and Gynecology in 2019, sexual function in the women with vulva pain improved with oral nerve pain medication named Gabapentin.

The Tricyclic antidepressants (TCAs) segment is also expected to grow at a high rate over the forecast period. Tricyclic antidepressants (TCAs) are a class of medication that are used primarily as antidepressants. Examples of tablets include amitriptyline, dothiepin, and nortriptyline. Other antidepressants like venlafaxine can also be tried. As the treatment of vulvodynia is mainly centered at placebo, antidepressants are the first form of medical treatment given to a patient in case of minor pains.

Source: DataM Intelligence Analysis (2019)

Geographical Analysis

Geographically, the global vulvodynia treatment market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

North America is dominating the global vulvodynia treatment market in 2018 and is estimated to hold significant market size over the forecast period (2020-2027) owing to the rising prevalence of vulvodynia, and the presence of ongoing research and development activities in the region.

The rising prevalence of vulvodynia is expected to drive the growth of the market over the forecast period. For instance, according to the NIH-funded Harvard study, an estimated 6 million women in America will suffer from Vulvodynia. Despite the high number of those affected, the pain is left misdiagnosed or untreated. A survey conducted by the University of Michigan found that, out of the 2,269 women in the metro-Detroit area, 25 % said that they had experienced vulvar pain. Among the 25 %, only 2 % admitted to seeking medical treatment for the pain. Although it is shocking to know that few women speak up about their pain, even more, alarming is that those that discussed the discomfort with their doctor were misdiagnosed. Also, according to the US’s National Vulvodynia Association, as many as 16% of women experience the condition at some point.

The presence of ongoing research and development activities on vulvodynia treatment is expected to drive market growth over the forecast period. For instance,  

University/Center

Intervention

Indication

Anticipated launch

McLean Center for Complementary and Alternative Medicine, PLC

Acupuncture

Vulvodynia

December 2021

The University of Illinois at Chicago

Acupuncture

Vulvodynia

September 2022

Source: DataM Intelligence Analysis (2019)

Competitive Landscape

The major players operating in the global vulvodynia treatment market are Allergan, Janssen Pharmaceuticals (Johnson and Johnson), GTO Pharmaceutical, LLC, and Ipsen Pharma.

The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, which are contributing to the growth of the vulvodynia treatment market globally. For instance,

On January 11, 2019, Ipsen Pharma demonstrated a leadership position in neurotoxin research with a strong presence at TOXINS 2019.

Why Purchase the Report?

  • Visualize the composition of the global vulvodynia treatment market across each drug type, and end-user highlighting the key commercial assets and players.

  • Identify commercial opportunities in the global vulvodynia treatment market by analyzing trends and co-development deals.

  • Excel data sheet with thousands of data points of the global vulvodynia treatment market-level 4/5 segmentation.

  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

  • Type mapping in excel for the key Services of all major market players.

The Global Vulvodynia Treatment Market report would provide access to an approx, 44 market data tables, 48 figures, and 220 pages.

Target Audience:

  • Equipment Suppliers/ Buyers

  • Type Providers/ Buyers

  • Industry Investors/Investment Bankers

  • Education & Research Institutes

  • Research Professionals

  • Emerging Companies

  • Manufacturers

 

Table of Content

  1. Vulvodynia Treatment Market - Methodology and Scope

    1. Research Methodology
    2. Research Objective and Scope of the Report
  2. Vulvodynia Treatment Market – Market Definition and Overview

  3. Vulvodynia Treatment  Market – Executive Summary

    1. Market Snippet by Drug type
    2. Market Snippet by End-user
  4. Vulvodynia Treatment Market - Market Dynamics

    1. Market Impacting Factors
    2. Drivers
      1. The presence of an increased number of research and development activities
      2. The presence of a promising product pipeline
    3. Restraints
      1. The onset of side effects
    4. Opportunity
    5. Impact Analysis
  5. Vulvodynia Treatment Market – Industry Analysis

    1. Porter's Five Forces Analysis
    2. Regulatory Analysis
    3. Supply Chain Analysis
    4. Pricing Analysis
    5. Unmet Needs
  6. Vulvodynia Treatment Market - By Drug type

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug type
      2. Market Attractiveness Index, By Drug type Segment
    2. Anticonvulsants*
      1. Introduction
      2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026
    3. Tricyclic antidepressants
    4. Local anesthetics
    5. Antimicrobials
    6. Hormone creams
    7. Nerve blocks
    8. Others
  7. Vulvodynia Treatment Market - By End-user

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
      2. Market Attractiveness Index, By End-user Segment
    2. Hospital pharmacies*
      1. Introduction
      2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026
    3. Retail pharmacies
    4. Online pharmacies
  8. Vulvodynia Treatment Market - By Region

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
      2. Market Attractiveness Index, By Region
    2. North America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. The U.S.
        2. Canada
        3. Mexico
    3. Europe
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Germany
        2. The U.K.
        3. France
        4. Italy
        5. Spain
        6. Rest of Europe
    4. South America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Brazil
        2. Argentina
        3. Rest of South America
    5. Asia Pacific
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. China
        2. India
        3. Japan
        4. Australia
        5. Rest of Asia Pacific
    6. The Middle East and Africa
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
  9. Vulvodynia Treatment Market - Competitive Landscape

    1. Competitive Scenario
    2. Market Positioning/Share Analysis
    3. Mergers and Acquisitions Analysis
  10. Vulvodynia Treatment Market - Company Profiles

    1. Allergan*
      1. Company Overview
      2. Product Portfolio and Description
      3. Key Highlights
      4. Financial Overview
    2. Janssen Pharmaceuticals (Johnson and Johnson)
    3. GTO Pharmaceutical, LLC
    4. Ipsen Pharma (List Not Exhaustive)
  11. Vulvodynia Treatment Market – Premium Insights

  12. Vulvodynia Treatment Market – Data-M

    1. Appendix
    2. About Us and Services
    3. Contact Us

List of Tables & Figures

List of Tables

TABLE 01 GLOBAL VULVODYNIA TREATMENT MARKET VALUE, BY DRUG TYPE, 2018, 2022 & 2027 ($ MILLION)

TABLE 02 GLOBAL VULVODYNIA TREATMENT MARKET VALUE, BY END-USER, 2018, 2022 & 2027 ($ MILLION)

TABLE 03 GLOBAL VULVODYNIA TREATMENT MARKET VALUE, BY REGION, 2018, 2022 & 2027 ($ MILLION)

TABLE 04 GLOBAL VULVODYNIA TREATMENT MARKET VALUE, BY COUNTRY, 2018, 2022 & 2027 ($ MILLION)

TABLE 05 GLOBAL VULVODYNIA TREATMENT MARKET VALUE, BY DRUG TYPE, 2018, 2022 & 2027 ($ MILLION)

TABLE 06 GLOBAL VULVODYNIA TREATMENT MARKET VALUE, BY DRUG TYPE, 2017-2027 ($ MILLION)

TABLE 07 GLOBAL VULVODYNIA TREATMENT MARKET VALUE, BY END-USER, 2018, 2022 & 2027 ($ MILLION)

TABLE 08 GLOBAL VULVODYNIA TREATMENT MARKET VALUE, BY END-USER, 2017-2027 ($ MILLION)

TABLE 09 GLOBAL VULVODYNIA TREATMENT MARKET VALUE, BY REGION, 2018, 2022 & 2027 ($ MILLION)

TABLE 10 GLOBAL VULVODYNIA TREATMENT MARKET VALUE, BY REGION, 2017-2027 ($ MILLION)

TABLE 11 GLOBAL VULVODYNIA TREATMENT MARKET VALUE, BY COUNTRY, 2018, 2022 & 2027 ($ MILLION)

TABLE 12 GLOBAL VULVODYNIA TREATMENT MARKET VALUE, BY COUNTRY, 2017-2027 ($ MILLION)

TABLE 13 NORTH AMERICA VULVODYNIA TREATMENT MARKET VALUE, BY DRUG TYPE, 2017-2027 ($ MILLION)

TABLE 14 NORTH AMERICA VULVODYNIA TREATMENT MARKET VALUE, BY END-USER, 2017-2027 ($ MILLION)

TABLE 15 NORTH AMERICA VULVODYNIA TREATMENT MARKET VALUE, BY REGION, 2017-2027 ($ MILLION)

TABLE 16 NORTH AMERICA VULVODYNIA TREATMENT MARKET VALUE, BY COUNTRY, 2017-2027 ($ MILLION)

TABLE 17 SOUTH AMERICA VULVODYNIA TREATMENT MARKET VALUE, BY DRUG TYPE, 2017-2027 ($ MILLION)

TABLE 18 SOUTH AMERICA VULVODYNIA TREATMENT MARKET VALUE, BY END-USER, 2017-2027 ($ MILLION)

TABLE 19 SOUTH AMERICA VULVODYNIA TREATMENT MARKET VALUE, BY REGION, 2017-2027 ($ MILLION)

TABLE 20 SOUTH AMERICA VULVODYNIA TREATMENT MARKET VALUE, BY COUNTRY, 2017-2027 ($ MILLION)

TABLE 21 EUROPE VULVODYNIA TREATMENT MARKET VALUE, BY DRUG TYPE, 2017-2027 ($ MILLION)

TABLE 22 EUROPE VULVODYNIA TREATMENT MARKET VALUE, BY END-USER, 2017-2027 ($ MILLION)

TABLE 23 EUROPE VULVODYNIA TREATMENT MARKET VALUE, BY REGION, 2017-2027 ($ MILLION)

TABLE 24 EUROPE VULVODYNIA TREATMENT MARKET VALUE, BY COUNTRY, 2017-2027 ($ MILLION)

TABLE 25 ASIA-PACIFIC VULVODYNIA TREATMENT MARKET VALUE, BY DRUG TYPE, 2017-2027 ($ MILLION)

TABLE 26 ASIA-PACIFIC VULVODYNIA TREATMENT MARKET VALUE, BY END-USER, 2017-2027 ($ MILLION)

TABLE 27 ASIA-PACIFIC VULVODYNIA TREATMENT MARKET VALUE, BY REGION, 2017-2027 ($ MILLION)

TABLE 28 ASIA-PACIFIC VULVODYNIA TREATMENT MARKET VALUE, BY COUNTRY, 2017-2027 ($ MILLION)

TABLE 29 MIDDLE EAST & AFRICA VULVODYNIA TREATMENT MARKET VALUE, BY DRUG TYPE, 2017-2027 ($ MILLION)

TABLE 30 MIDDLE EAST & AFRICA VULVODYNIA TREATMENT MARKET VALUE, BY END-USER, 2017-2027 ($ MILLION)

TABLE 31 MIDDLE EAST & AFRICA VULVODYNIA TREATMENT MARKET VALUE, BY REGION, 2017-2027 ($ MILLION)

TABLE 32 MIDDLE EAST & AFRICA VULVODYNIA TREATMENT MARKET VALUE, BY COUNTRY, 2017-2027 ($ MILLION)

TABLE 33 ALLERGAN: OVERVIEW

TABLE 34 ALLERGAN: PRODUCT PORTFOLIO

TABLE 35 ALLERGAN: KEY DEVELOPMENTS

TABLE 36 JANSSEN PHARMACEUTICALS (JOHNSON AND JOHNSON): OVERVIEW

TABLE 37 JANSSEN PHARMACEUTICALS (JOHNSON AND JOHNSON): PRODUCT PORTFOLIO

TABLE 38 JANSSEN PHARMACEUTICALS (JOHNSON AND JOHNSON): KEY DEVELOPMENTS

TABLE 39 GTO PHARMACEUTICAL, LLC: OVERVIEW

TABLE 40 GTO PHARMACEUTICAL, LLC: PRODUCT PORTFOLIO

TABLE 41 GTO PHARMACEUTICAL, LLC: KEY DEVELOPMENTS

TABLE 42 IPSEN PHARMA: OVERVIEW

TABLE 43 IPSEN PHARMA: PRODUCT PORTFOLIO

TABLE 44 IPSEN PHARMA: KEY DEVELOPMENTS

 

List Of Figures 

FIGURE 01 GLOBAL VULVODYNIA TREATMENT MARKET SHARE, BY DRUG TYPE, 2018 & 2027 (%) 

FIGURE 02 GLOBAL VULVODYNIA TREATMENT MARKET SHARE, BY END-USER, 2018 & 2027 (%) 

FIGURE 03 GLOBAL VULVODYNIA TREATMENT MARKET SHARE, BY REGION, 2018 & 2027 (%) 

FIGURE 04 GLOBAL VULVODYNIA TREATMENT MARKET SHARE, BY COUNTRY, 2018 & 2027 (%) 

FIGURE 05 GLOBAL VULVODYNIA TREATMENT MARKET VALUE, 2017-2027 ($ MILLION) 

FIGURE 06 GLOBAL VULVODYNIA TREATMENT MARKET Y-O-Y GROWTH, BY DRUG TYPE, 2018-2027 (%) 

FIGURE 07 ANTICONVULSANTS: GLOBAL VULVODYNIA TREATMENT MARKET VALUE, 2017-2027 ($ MILLION) 

FIGURE 08 TRICYCLIC ANTIDEPRESSANTS: GLOBAL VULVODYNIA TREATMENT MARKET VALUE, 2017-2027 ($ MILLION) 

FIGURE 09 LOCAL ANESTHETICS: GLOBAL VULVODYNIA TREATMENT MARKET VALUE, 2017-2027 ($ MILLION) 

FIGURE 10 ANTIMICROBIALS: GLOBAL VULVODYNIA TREATMENT MARKET VALUE, 2017-2027 ($ MILLION) 

FIGURE 11 HORMONE CREAMS: GLOBAL VULVODYNIA TREATMENT MARKET VALUE, 2017-2027 ($ MILLION) 

FIGURE 12 NERVE BLOCKS: GLOBAL VULVODYNIA TREATMENT MARKET VALUE, 2017-2027 ($ MILLION) 

FIGURE 13 OTHERS: GLOBAL VULVODYNIA TREATMENT MARKET VALUE, 2017-2027 ($ MILLION) 

FIGURE 14 GLOBAL VULVODYNIA TREATMENT MARKET Y-O-Y GROWTH, BY END-USER, 2018-2027 (%) 

FIGURE 15 HOSPITAL PHARMACIES: GLOBAL VULVODYNIA TREATMENT MARKET VALUE, 2017-2027 ($ MILLION) 

FIGURE 16 ONLINE PHARMACIES: GLOBAL VULVODYNIA TREATMENT MARKET VALUE, 2017-2027 ($ MILLION) 

FIGURE 17 RETAIL PHARMACIES: GLOBAL VULVODYNIA TREATMENT MARKET VALUE, 2017-2027 ($ MILLION) 

FIGURE 18 GLOBAL VULVODYNIA TREATMENT MARKET Y-O-Y GROWTH, BY REGION, 2018-2027 (%) 

FIGURE 19 GLOBAL VULVODYNIA TREATMENT MARKET Y-O-Y GROWTH, BY COUNTRY, 2018-2027 (%) 

FIGURE 20 NORTH AMERICA VULVODYNIA TREATMENT MARKET VALUE, 2017-2027 ($ MILLION) 

FIGURE 21 NORTH AMERICA VULVODYNIA TREATMENT MARKET SHARE, BY DRUG TYPE, 2018 & 2027 (%) 

FIGURE 22 NORTH AMERICA VULVODYNIA TREATMENT MARKET SHARE, BY END-USER, 2018 & 2027 (%) 

FIGURE 23 NORTH AMERICA VULVODYNIA TREATMENT MARKET SHARE, BY REGION, 2018 & 2027 (%) 

FIGURE 24 NORTH AMERICA VULVODYNIA TREATMENT MARKET SHARE, BY COUNTRY, 2018 & 2027 (%) 

FIGURE 25 SOUTH AMERICA VULVODYNIA TREATMENT MARKET VALUE, 2017-2027 ($ MILLION) 

FIGURE 26 SOUTH AMERICA VULVODYNIA TREATMENT MARKET SHARE, BY DRUG TYPE, 2018 & 2027 (%) 

FIGURE 27 SOUTH AMERICA VULVODYNIA TREATMENT MARKET SHARE, BY END-USER, 2018 & 2027 (%) 

FIGURE 28 SOUTH AMERICA VULVODYNIA TREATMENT MARKET SHARE, BY REGION, 2018 & 2027 (%) 

FIGURE 29 SOUTH AMERICA VULVODYNIA TREATMENT MARKET SHARE, BY COUNTRY, 2018 & 2027 (%) 

FIGURE 30 EUROPE VULVODYNIA TREATMENT MARKET VALUE, 2017-2027 ($ MILLION) 

FIGURE 31 EUROPE VULVODYNIA TREATMENT MARKET SHARE, BY DRUG TYPE, 2018 & 2027 (%) 

FIGURE 32 EUROPE VULVODYNIA TREATMENT MARKET SHARE, BY END-USER, 2018 & 2027 (%) 

FIGURE 33 EUROPE VULVODYNIA TREATMENT MARKET SHARE, BY REGION, 2018 & 2027 (%) 

FIGURE 34 EUROPE VULVODYNIA TREATMENT MARKET SHARE, BY COUNTRY, 2018 & 2027 (%) 

FIGURE 35 ASIA-PACIFIC VULVODYNIA TREATMENT MARKET VALUE, 2017-2027 ($ MILLION) 

FIGURE 36 ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SHARE, BY DRUG TYPE, 2018 & 2027 (%) 

FIGURE 37 ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SHARE, BY END-USER, 2018 & 2027 (%) 

FIGURE 38 ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SHARE, BY REGION, 2018 & 2027 (%) 

FIGURE 39 ASIA-PACIFIC VULVODYNIA TREATMENT MARKET SHARE, BY COUNTRY, 2018 & 2027 (%) 

FIGURE 40 MIDDLE EAST & AFRICA VULVODYNIA TREATMENT MARKET VALUE, 2017-2027 ($ MILLION) 

FIGURE 41 MIDDLE EAST & AFRICA VULVODYNIA TREATMENT MARKET SHARE, BY DRUG TYPE, 2018 & 2027 (%) 

FIGURE 42 MIDDLE EAST & AFRICA VULVODYNIA TREATMENT MARKET SHARE, BY END-USER, 2018 & 2027 (%) 

FIGURE 43 MIDDLE EAST & AFRICA VULVODYNIA TREATMENT MARKET SHARE, BY REGION, 2018 & 2027 (%) 

FIGURE 44 MIDDLE EAST & AFRICA VULVODYNIA TREATMENT MARKET SHARE, BY COUNTRY, 2018 & 2027 (%) 

FIGURE 45 ALLERGAN: FINANCIALS 

FIGURE 46 JANSSEN PHARMACEUTICALS (JOHNSON AND JOHNSON): FINANCIALS 

FIGURE 47 GTO PHARMACEUTICAL, LLC: FINANCIALS 

FIGURE 48 IPSEN PHARMA: FINANCIALS 

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Get your FREE SAMPLE PROPOSAL with a single click!

linkedinpinterest